AMRI, a contract research, development, and manufacturing organization, has signed a seven-year contract with the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to manufacture active pharmaceutical ingredients (APIs) and drug products.

AMRI’s activities under the contract will focus on the development and manufacture of APIs and drug products for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s facilities in Albany, New York.

AMRI has other contracts with NIH research programs, which include the company’s selection as a Dedicated Chemical Biology Consortium as well as participation in the Center for the NCI Experimental Therapeutics Program, the National Center for Advancing Translational Sciences, and the Blueprint Neurotherapeutics Network (BPN).

In April 2018, AMRI renewed a 10-year contract worth up to $39.5 million with the NIH BPN to provide the BPN with medicinal chemistry and absorption, distribution, metabolism and excretion services focused on advancing drug-discovery programs in neurotherapeutics.